Mohamed Sharif

Mohamed Sharif

Auto-generated profile, based on publicly available information

Mohamed Sharif

Department of Cancer Genetics & Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Applied Ergonomics
Verified
Journal Article
Closed access
JTJudith Tiferes
Judith Tiferes
AHAhmed A. Hussein
Ahmed A. Hussein
ABAnn Bisantz
Ann Bisantz
DHD. Jeffery Higginbotham
D. Jeffery Higginbotham
MSMohamed Sharif
Mohamed Sharif
KGKhurshid Guru
Khurshid Guru

23 July 2018 in Canadian Urological Association Journal
Verified
Journal Article
Open access
PDF file
HKHijab Khan
Hijab Khan
JKJusten D. Kozlowski
Justen D. Kozlowski
AAAhmed Aly Hussein Aly
Ahmed Aly Hussein Aly
MSMohamed Sharif
Mohamed Sharif
YAYoussef Ahmed
Youssef Ahmed
KGKhurshid Ahad Guru
Khurshid Ahad Guru
Introduction: We sought to evaluate the Robotic Anastomosis Competency Evaluation (RACE) — a validated tool that objectively quantifies surgical skills specifically for urethrovesical anastomosis (UVA) — as a means to track progress of trainees, as well as to determine its predictive value. Methods: UVAs performed by trainees at our institution were evaluated using RACE over a period of two years. Trainees were supervised by an experienced robotic surgeon. Outcomes included traineerelated variables (RACE score, proportion of UVA performed by trainee, and suturing speed), and clinical outcomes (total UVA duration, postoperative urinary continence, and UVA-related complications). Significance was determined using linear regression analysis. Results: A total of 51 UVAs performed by six trainees were evaluated. Trainee RACE scores (19.8 to 22.3; p=0.01) and trainee proportion of UVA (67% to 80%; p=0.003) improved significantly over time. Trainee suture speed was significantly associated with RACE score (mean speed range 0.54–0.74 sutures/minute; p=0.03). Neither urinary continence at six weeks nor at six months was significantly associated with RACE score (p=0.17 and p=0.15, respectively), and only one UVA-related postoperative complication was reported. Conclusions: Trainee RACE scores improved and the proportion of UVA performed by trainees increased over time. RACE can be used as an objective measure of surgical performance during training. Strict mentor supervision allowed safe training without compromising patient outcomes.

4 August 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
MSMohamed A. Sharif
Mohamed A. Sharif
AKAbdul S. Khan
Abdul S. Khan
RBRenier J. Brentjens
Renier J. Brentjens
SOScott H Olejniczak
Scott H Olejniczak
HWHenry G. Withers
Henry G. Withers
JOJoyce Ellen Ohm
Joyce Ellen Ohm
Ewing sarcoma (EwS) is an aggressive pediatric malignancy with poor outcomes for patients with metastatic or relapsed disease. Effective immunotherapeutic approaches, including CAR T-cell therapy, are limited by intratumoral heterogeneity, an incompletely characterized tumor microenvironment (TME), and a lack of well-defined, tumor-restricted target antigens. To address these limitations, we performed an integrated analysis of EwS tumor samples using both single-nucleus and single-cell RNA sequencing datasets derived exclusively from patient samples, including matched primary tumors and orthotopic patient-derived xenograft (PDX) models. Our analyses reveal that primary EwS tumors are largely composed of highly heterogeneous malignant cell populations occupying multiple, multidirectional transcriptional states, including neuronal-like, proliferative, angiogenic, and fibroblast-like. We demonstrate that the EwS TME contains both classical cancer-associated fibroblasts (CAFs) and abundant EwS CAF-like tumor cells that transcriptionally resemble stromal cells while retaining tumor identity. Trajectory analyses define a progressive and coordinated tumor–CAF continuum, marked by gradual loss of neuronal programs and activation of mesenchymal and extracellular matrix remodeling programs, suggesting dynamic tumor cell reprogramming that may promote invasion, immune evasion, and therapeutic resistance. Notably, this structured transcriptional continuum was prominent in primary tumors but largely absent in matched PDX models, underscoring the importance of native tumor context for capturing clinically relevant tumor–TME interactions. We also developed a systematic surface-antigen discovery pipeline and identified ten novel putative tumor-associated surface target antigens (TAs), LRRC15, ATP2B3, CACNA1I, DCHS2, DSEL, LPAR4, PRRT4, TMEM229A, UNC5A, and UNC79, none of which have been previously described in EwS tumor biology. Characterization of these surface TAs revealed distinct expression patterns across EwS tumor cells, EwS CAF-like tumor cells, and classical CAFs. Moreover, some TAs expression differed between primary and metastatic tumors and between primary patient samples and matched PDX models, highlighting the critical importance of first validating therapeutic targets in primary tissues (PT). Together, these findings redefine the cellular architecture of EwS by revealing a dynamic tumor–CAF continuum that is uniquely preserved in primary tumors and establishes a framework for identifying clinically relevant tumor-associated surface TAs. These results provide a foundation for the rational development of next-generation immunotherapies and precision-targeted therapies for patients with EwS.